Project Grant R21AA031725

Award Date 9/5/24
Completion Date 8/31/26
Dollars Obligated $410K
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
Rootstown, OH 44272, USA
Similar Awards
The University of California, San Diego (UCSD) was awarded a $414,750 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to investigate the role of intestinal gp130 signaling in preventing alcohol-associated liver disease. The proposed research aims to define the gp130-STAT3-Reg3 signaling axis involved in protecting against ethanol-induced liver disease and assess the potential of a novel engineered gp130...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $701,051 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research on "Innate Immune Dysregulation in Alcohol-Associated Liver Disease." The project aims to characterize neutrophil dysfunction and related molecular mechanisms in severe alcohol-associated hepatitis, with the goal of developing targeted interventions to reduce...
This federal Project Grant award for $3,182,397.00 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to the University of California, San Diego (UCSD) to research the role of intestinal proteases, specifically cathepsin B (CTSB), in contributing to gut barrier dysfunction and the progression of alcohol-associated liver disease. The key products and services to be delivered under this 4-year award include:...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $177,736 Project Grant under CFDA 93.273, the Alcohol Research Programs, to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to investigate the role of hepatokines, predominantly hepatocyte-secreted proteins, in alcohol-associated liver disease (ALD) and alcohol-associated hepatitis (AH). The research aims to elucidate the mechanisms by which hepatocytes alter immune cell function in AH, with a focus on the hepatokine...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $438,375 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Cedars-Sinai Medical Center to establish a human liver-on-a-chip model for studying alcohol-associated liver disease (ALD). The 2-year project, starting September 2023, aims to investigate the roles of liver sinusoidal endothelial cells and acetaldehyde metabolism in regulating ethanol-induced liver damage as well as the contribution of fibrotic...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,376,398.00 Project Grant under CFDA 93.273 Alcohol Research Programs to Yale University. The 5-year grant, with a start date of June 1, 2025 and an ultimate completion date of February 28, 2030, supports the development of a humanized mouse model to study the key features of alcohol-associated hepatitis (AAH), a leading cause of liver-related deaths worldwide. The project aims to create a fully humanized mouse liver...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $249,000 project grant to the Trustees of Indiana University, doing business as Indiana University Indianapolis, to investigate the role of neutrophilic NCF1 in the pathogenesis of alcohol-associated liver disease. The research project aims to elucidate the molecular mechanisms by which NCF1, a key regulator of reactive oxygen species production in neutrophils, inhibits...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $253,383 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to explore the role of the hepatocyte inflammasome in alcoholic liver disease (AALD). The project aims to investigate the liver-specific effects of the inflammasome component caspase-1 in hepatocytes, the predominant liver cell type, and its influence on the pathophysiology of AALD. Through in vivo and in vitro experiments, the...
This federal Project Grant award, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), will fund research to uncover the functional and mechanistic dysregulation of monocytes after abstinence and post-abstinence drinking in a rhesus macaque model. The $105,132 award to the University of Kentucky Research Foundation will support investigations into how chronic heavy drinking induces persistent changes in peripheral monocytes...
The Cedars-Sinai Medical Center was awarded a $617,748 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs) to study the role of Prohibitin 1 (PHB1) protein in the sensitizing effect of ethanol on colorectal liver metastasis. The research aims to examine how ethanol depletion of nuclear and cytosolic PHB1 in hepatocytes increases the expression of matrix metalloproteinase-7 (MMP-7), thereby promoting the spread of colorectal cancer...

ALCOHOL IMPAIRS THE HSPC RESPONSE TO SEPTIC INFECTION - PROJECT SUMMARY/ABSTRACT ALCOHOL ABUSE INCREASES THE HOST RISK OF DEVELOPING SERIOUS INFECTIONS, PARTICULARLY SEPTICEMIA/SEPSIS. NEUTROPHIL GRANULOCYTES CONSTITUTE THE FIRST LINE OF PHAGOCYTIC DEFENSE AGAINST BACTERIAL PATHOGENS. OUR RECENT STUDIES HAVE DEMONSTRATED THAT ACTIVATION OF HEMATOPOIETIC STEM CELLS (HSCS) IS CRUCIAL FOR ENHANCING GRANULOCYTE PRODUCTION BY BONE MARROW IN RESPONSE TO BACTERIAL INFECTION. ALCOHOL IMPAIRS THIS CRITICAL STEP OF THE GRANULOPOIETIC RESPONSE. CURRENTLY, KNOWLEDGE ABOUT THE UNDERLYING MECHANISMS REMAINS LIMITED. GUANYLATE-BINDING PROTEIN 7 (GBP7) IS A MEMBER OF THE 65KDA LARGE CYTOKINE INDUCIBLE GTPASE FAMILY. LITTLE IS KNOWN ABOUT THE FUNCTION OF GBP7 IN HEMATOPOIETIC STEM/PROGENITOR CELLS (HSPCS). OUR PILOT STUDIES REVEALED THAT GBP7 EXPRESSION BY HSPCS WAS MARKEDLY UPREGULATED AT BOTH MRNA AND PROTEIN LEVELS IN MICE WITH E. COLI SEPTICEMIA. THIS INCREASE IN GBP7 EXPRESSION WAS ACCOMPANIED BY ACTIVATION OF HSPCS. CHRONIC PLUS BINGE ALCOHOL ADMINISTRATION SUPPRESSED THE UPREGULATION OF GBP7 EXPRESSION ALONG WITH INHIBITION OF HSPC ACTIVATION DURING E. COLI SEPTICEMIA. SEARCHING PROMOTER REGIONS OF MURINE AND HUMAN GBP7 GENES SHOWED MULTIPLE FOS/JUN BINDING SITES. ALCOHOL SUPPRESSED ACTIVATION OF C-JUN N-TERMINAL KINASES (JNK1/2) IN MARROW CELLS DURING SEPTICEMIA. INHIBITION OF JNK1/2 ACTIVATION WITH SPECIFIC INHIBITOR SUPPRESSED LIPOPOLYSACCHARIDE- INDUCED UP-REGULATION OF GBP7 EXPRESSION BY HSPCS. THE PREDOMINANT DISTRIBUTION OF GBP7 WAS DETECTED IN NUCLEI OF HSPCS FROM BOTH MURINE AND HUMAN ORIGINS. SEPTIC STIMULI CAUSED A MARKED ENHANCEMENT OF GBP7 EXPRESSION IN THE NUCLEI OF HSPCS, WHICH IMPLIED A CLOSE ASSOCIATION OF GBP7 WITH THE CHANGE IN NUCLEAR ACTIVITY. GBP ACTIVATION LEADS TO THEIR CONFORMATIONAL CHANGES FACILITATING INTERACTION OF THESE LARGE GTPASES WITH DIFFERENT MACROMOLECULES TO FORM COMPLEXES FOR CARRYING OUT DIFFERENT FUNCTIONS IN CELLS. CYCLIN D1-CYCLIN- DEPENDENT KINASE (CDK) 4/6 SIGNALING DRIVES HSPC PROLIFERATION. SEPTICEMIA CAUSED A MARKED INCREASE IN CYCLIN D1 EXPRESSION AND ENHANCEMENT OF PROLIFERATION IN HSPCS, BOTH OF WHICH WERE SUPPRESSED BY ALCOHOL OR GBP7 KNOCKOUT (KO). GBP7 KO IMPAIRED MARROW GRANULOPOIETIC RESPONSE, WHICH WAS SIMILAR TO WHAT CAUSED BY ALCOHOL INTOXICATION. OUR CURRENT PROJECT PROPOSES TO EXPLORE THE ROLE OF GBP7 IN THE REGULATION OF HSPC ACTIVATION AND INVESTIGATE HOW ALCOHOL IMPAIRS IT. THE CENTRAL HYPOTHESIS IS THAT ALCOHOL INHIBITS GBP7 SIGNALING FOR HSPC ACTIVATION DURING THE GRANULOPOIETIC RESPONSE TO SEPTIC INFECTION. TWO SPECIFIC AIMS ARE: 1) TO EXAMINE IF ALCOHOL SUPPRESSES UP-REGULATION OF GBP7 EXPRESSION BY HSPCS VIA INHIBITING ACTIVATION OF THE TOLL- LIKE RECEPTOR (TLR) 4-JNK1/2-FOS/JUN PATHWAY IN RESPONSE TO SEPTIC INFECTION; 2) TO DETERMINE IF ALCOHOL INHIBITS HSPC ACTIVATION DURING THE GRANULOPOIETIC RESPONSE VIA IMPAIRING GBP7-CYCLIN D1-CDK4/6 SIGNALING. RESULTS OBTAINED FROM THIS EXPLORATORY INVESTIGATION WILL GREATLY ADVANCE OUR KNOWLEDGE ABOUT THE DEFECT OF IMMUNE DEFENSE AGAINST SERIOUS INFECTION IN ALCOHOL ABUSERS. IT WILL ALSO IDENTIFY KEY TARGETS FOR FURTHER DEVELOPING NOVEL THERAPEUTIC INTERVENTIONS TO TREAT FATAL INFECTION AND SEPSIS IN THESE IMMUNOCOMPROMISED HOSTS.

Posted 9/5/24